Eculizumab in chemotherapy-induced thrombotic microangiopathy
نویسندگان
چکیده
منابع مشابه
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
BACKGROUND Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic cancers. The mainstay of management is withdrawal of the offending drug and supportive care. Plasmapheresi...
متن کاملThrombotic Microangiopathy Induced by Hyperthermal Intraperitoneal Chemotherapy with Mitomycin C
A patient with pseudomyxoma peritonei underwent Hyperthermal Intraperitoneal Chemotherapy (HIPEC) with Mitomycin C after which she developed thrombotic microangiopathy. This syndrome mimicked possible surgical complications. Treatment with plasma exchange resolved the syndrome and the patient recovered completely. This is the first description of thrombotic microangiopathy early after a single ...
متن کاملRole of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
BACKGROUND The incidence of gemcitabine-induced hemolytic uremic syndrome has already been described in adults. Several approaches have been employed in the treatment of gemcitabine-induced hemolytic uremic syndrome with different outcomes. One of the most promising agents is eculizumab, which is a monoclonal antibody directed against C5 complement protein. CASE PRESENTATION We reported the c...
متن کاملThrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
BACKGROUND Interferon-beta (IFN-beta) is one of the most widely prescribed medications for relapsing-remitting multiple sclerosis (RRMS). IFN-related thrombotic microangiopathy (TMA) is a rare but severe complication, with a fulminant clinical onset and a possibly life-threatening outcome that may occur years after a well-tolerated treatment with IFN. Most patients evolve rapidly to advanced ch...
متن کاملGemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
Drug-induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro-inflammatory surge. Furthermore, adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Nephrology – Case Studies
سال: 2020
ISSN: 2196-5293
DOI: 10.5414/cncs109836